Citations (65)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Avram Fraint, Padmaja Vittal & Cynthia Comella. (2016) Considerations on patient-related outcomes with the use of botulinum toxins: is switching products safe?. Therapeutics and Clinical Risk Management 12, pages 147-154.
Read now
Read now
Pierre Denys, Jacques Corcos, Karel Everaert, Emmanuel Chartier-Kastler, Clare Fowler, Vinay Kalsi, Victor Nitti, Heinrich Schulte-Baukloh & Brigitte Schurch. (2006) Improving the global management of the neurogenic bladder patient: part II.Future treatment strategies. Current Medical Research and Opinion 22:5, pages 851-860.
Read now
Read now
Articles from other publishers (63)
Aaron Jamison, Maribel Favor & Raman Malhotra. (2022) Patient-reported outcomes following a break in ophthalmic botulinum toxin therapy during the COVID-19 pandemic. Canadian Journal of Ophthalmology.
Crossref
Crossref
Claudia Ledda, Carlo Alberto Artusi, Antonella Tribolo, Domiziana Rinaldi, Gabriele Imbalzano, Leonardo Lopiano & Maurizio Zibetti. (2022) Time to onset and duration of botulinum toxin efficacy in movement disorders. Journal of Neurology 269:7, pages 3706-3712.
Crossref
Crossref
Raja Mehanna & Joseph Jankovic. 2022. Handbook of Neurotoxicity. Handbook of Neurotoxicity
1095
1143
.
Nicola Tambasco, Marta Filidei, Pasquale Nigro, Lucilla Parnetti & Simone Simoni. (2021) Botulinum Toxin for the Treatment of Hemifacial Spasm: An Update on Clinical Studies. Toxins 13:12, pages 881.
Crossref
Crossref
Incı Sule Ozer, Muge Kuzu Kumcu, Sabiha Tezcan Aydemir & Muhittin Cenk Akbostanci. (2021) Dose conversion ratio, comparative efficacy, and adverse events after switching from onabotulinum toxin A to abobotulinum toxin A for neurological conditions. Clinical Neurology and Neurosurgery 209, pages 106889.
Crossref
Crossref
Yolanda Herrero-Infante, Ana Rodríguez-Sanz, Jorge Máñez-Miró & Francisco Vivancos-Matellano. (2021) Hemifacial spasm through the last three decades: From etiology to efficacy and safety of long-term botulinum toxin treatment. Clinical Neurology and Neurosurgery 203, pages 106555.
Crossref
Crossref
Samih Badarny, Raphiq Ibrahim, Zvi Susel, Adnan Zaina, Rema Nasar & Yazid Badarny. (2021) Long-term stable efficacy of botulinum toxin A in facial movement disorders with no need for increasing dose. Medicine 100:25, pages e26481.
Crossref
Crossref
Raja Mehanna & Joseph Jankovic. 2021. Handbook of Neurotoxicity. Handbook of Neurotoxicity
1
48
.
John C. Bladen, Maribel Favor, Andre Litwin & Raman Malhotra. (2020)
Switchover study of
onabotulinumtoxinA
to
incobotulinumtoxinA
for facial dystonia
. Clinical & Experimental Ophthalmology 48:9, pages 1146-1151.
Crossref
Crossref
Z.A. Zalyalova. (2020) Hemifacial spasm. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova 120:8, pages 140.
Crossref
Crossref
Alina Masters‐Israilov & Matthew S. Robbins. (2019) OnabotulinumtoxinA Wear‐off Phenomenon in the Treatment of Chronic Migraine. Headache: The Journal of Head and Face Pain 59:10, pages 1753-1761.
Crossref
Crossref
Shymaa A. Hablas, Doaa W. Nada, Doaa S. Alashkar & Ahmed A. Elsharkawy. (2019) The effect of botulinum toxin type A injection in decreasing intratunnel tendon tension in carpal tunnel syndrome: a randomized controlled trial for efficacy and safety. Egyptian Rheumatology and Rehabilitation 46:4, pages 299-303.
Crossref
Crossref
Babak Azizzadeh, Leslie E. Irvine, Jaqueline Diels, William H. Slattery, Guy G. Massry, Babak Larian, Kiersten L. Riedler & Grace Lee Peng. (2019) Modified Selective Neurectomy for the Treatment of Post–Facial Paralysis Synkinesis. Plastic & Reconstructive Surgery 143:5, pages 1483-1496.
Crossref
Crossref
John C Bladen, Ilan Feldman, Maribel Favor, Marizol Dizon, Andre Litwin & Raman Malhotra. (2018) Long-term outcome of flexible onabotulinum toxin A treatment in facial dystonia. Eye 33:3, pages 349-352.
Crossref
Crossref
Kristina Tedroff, Gustaf Befrits, Carl Johan Tedroff & Stefan Gantelius. (2018) To switch from Botox to Dysport in children with CP, a real world, dose conversion, cost-effectiveness study. European Journal of Paediatric Neurology 22:3, pages 412-418.
Crossref
Crossref
Christopher J. Hwang & Kian Eftekhari. (2018) Benign Essential Blepharospasm: What We Know and What We Don’t. International Ophthalmology Clinics 58:1, pages 11-24.
Crossref
Crossref
Kemar E. Green, David Rastall & Eric Eggenberger. (2017) Treatment of Blepharospasm/Hemifacial Spasm. Current Treatment Options in Neurology 19:11.
Crossref
Crossref
Atsushi Mizuma, Eiichiro Nagata, Takashi Yasuda, Maiko Kouchi, Taira Nakayama, Kazunari Honma, Kentaro Tokuoka, Yasuhisa Kitagawa, Shigeru Nogawa & Shunya Takizawa. (2017) Botulinum toxin A is effective to treat tension-type headache caused by hemifacial spasm. Journal of Clinical Neuroscience 44, pages 284-288.
Crossref
Crossref
Pamela Latino, Letizia Castelli, Luca Prosperini, Maria Rita Marchetti, Carlo Pozzilli & Morena Giovannelli. (2017) Determinants of botulinum toxin discontinuation in multiple sclerosis: a retrospective study. Neurological Sciences 38:10, pages 1841-1848.
Crossref
Crossref
Ryan M. Greene, John P. Arkins & Steven H. Dayan. 2017. Botulinum Toxins. Botulinum Toxins
121
131
.
Paul T. Bremer, Sabine Pellett, James P. Carolan, William H. Tepp, Lisa M. Eubanks, Karen N. Allen, Eric A. Johnson & Kim D. Janda. (2017) Metal Ions Effectively Ablate the Action of Botulinum Neurotoxin A. Journal of the American Chemical Society 139:21, pages 7264-7272.
Crossref
Crossref
Asmahan Alshubaili, Hussam Abou-Al-Shaar, Ponnusamy Santhamoorthy, Hosam Attia & Saeed Bohlega. (2016) Ultrasound-guided botulinum toxin A injection in the treatment of belly dancer’s dyskinesia. BMC Neurology 16:1.
Crossref
Crossref
Alberto Albanese, Giovanni Abbruzzese, Dirk Dressler, Wojciech Duzynski, Svetlana Khatkova, Maria Jose Marti, Pablo Mir, Cesare Montecucco, Elena Moro, Michaela Pinter, Maja Relja, Emmanuel Roze, Inger Marie Skogseid, Sofiya Timerbaeva & Charalampos Tzoulis. (2015) Practical guidance for CD management involving treatment of botulinum toxin: a consensus statement. Journal of Neurology 262:10, pages 2201-2213.
Crossref
Crossref
Alma Rystedt, Lena Zetterberg, Joachim Burman, Dag Nyholm & Anders Johansson. (2015) A Comparison of Botox 100 U/mL and Dysport 100 U/mL Using Dose Conversion Ratio 1. Clinical Neuropharmacology 38:5, pages 170-176.
Crossref
Crossref
Mine Hayriye Sorgun, Rezzak Yilmaz, Yusuf Alper Akin, Fatma Nazli Mercan & Muhittin Cenk Akbostanci. (2015) Botulinum toxin injections for the treatment of hemifacial spasm over 16years. Journal of Clinical Neuroscience 22:8, pages 1319-1325.
Crossref
Crossref
Ji Young Yun, Jae Woo Kim, Hee‐Tae Kim, Sun Ju Chung, Jong‐Min Kim, Jin Whan Cho, Jee‐Young Lee, Ha Neul Lee, Sooyeoun You, Eungseok Oh, Heejeong Jeong, Young Eun Kim, Han‐Joon Kim, Won Yong Lee & Beom S. Jeon. (2014) Dysport and Botox at a ratio of 2.5:1 units in cervical dystonia: A double‐blind, randomized study. Movement Disorders 30:2, pages 206-213.
Crossref
Crossref
Wallace A Marsh, Deirdre M Monroe, Mitchell F Brin & Conor J Gallagher. (2014) Systematic review and meta-analysis of the duration of clinical effect of onabotulinumtoxinA in cervical dystonia. BMC Neurology 14:1.
Crossref
Crossref
Arianna Guidubaldi, Anna Rita Bentivoglio & Alberto Albanese. 2014. Clinical Applications of Botulinum Neurotoxin. Clinical Applications of Botulinum Neurotoxin
51
93
.
Raja Mehanna & Joseph Jankovic. 2014. Handbook of Neurotoxicity. Handbook of Neurotoxicity
553
590
.
Alberto Albanese, Francesca Del Sorbo, Cynthia Comella, H. A. Jinnah, Jonathan W. Mink, Bart Post, Marie Vidailhet, Jens Volkmann, Thomas T. Warner, Albert F.G. Leentjens, Pablo Martinez-Martin, Glenn T. Stebbins, Christopher G. Goetz & Anette Schrag. (2013) Dystonia rating scales: Critique and recommendations. Movement Disorders 28:7, pages 874-883.
Crossref
Crossref
Hanan Mohamed El Kahky, Heba Mahmoud Diab, Dalia Gamal Aly & Nehal Magdi Farag. (2013) Efficacy of Onabotulinum Toxin A (Botox) versus Abobotulinum Toxin A (Dysport) Using a Conversion Factor (1 : 2.5) in Treatment of Primary Palmar Hyperhidrosis. Dermatology Research and Practice 2013, pages 1-6.
Crossref
Crossref
Daniel Truong. (2012) Botulinum toxins in the treatment of primary focal dystonias. Journal of the Neurological Sciences 316:1-2, pages 9-14.
Crossref
Crossref
Anna Rita Bentivoglio, Tàmara Ialongo, Francesco Bove, Francesca De Nigris & Alfonso Fasano. (2011) Retrospective evaluation of the dose equivalence of Botox® and Dysport® in the management of blepharospasm and hemifacial spasm: a novel paradigm for a never ending story. Neurological Sciences 33:2, pages 261-267.
Crossref
Crossref
Mattias LindeKnut HagenØyvind SalvesenGøril Bruvik GravdahlGrethe HeldeLars Jacob Stovner. (2011) Onabotulinum toxin A treatment of cervicogenic headache: A randomised, double-blind, placebo-controlled crossover study. Cephalalgia 31:7, pages 797-807.
Crossref
Crossref
K. Roger Aoki. 2011. Botulinum Toxins in Clinical Aesthetic Practice. Botulinum Toxins in Clinical Aesthetic Practice
1
14
.
A. Albanese, F. Asmus, K. P. Bhatia, A. E. Elia, B. Elibol, G. Filippini, T. Gasser, J. K. Krauss, N. Nardocci, A. Newton & J. Valls-Solé. (2011) EFNS guidelines on diagnosis and treatment of primary dystonias. European Journal of Neurology 18:1, pages 5-18.
Crossref
Crossref
Nils Erik Gilhus, Michael P. Barnes & Michael BraininA. Albanese, F. Asmus, A. Berardelli, K. Bhatia, A. E. Elia, B. Elibol, G. Filippini, T. Gasser, J. K. Krauss, N. Nardocci, A. Newton, J. Valls‐Solé & M. Vidailhet. 2010. European Handbook of Neurological Management. European Handbook of Neurological Management
191
206
.
Timothy Corcoran Flynn. (2010) Botulinum Toxin. American Journal of Clinical Dermatology 11:3, pages 183-199.
Crossref
Crossref
Jarosław Sławek, Halina Car, Marcin Bonikowski, Andrzej Bogucki, Dariusz Koziorowski, Anna Potulska-Chromik & Monika Rudzińska. (2010) Czy wszystkie preparaty toksyny botulinowej typu A są takie same? Porównanie trzech preparatów toksyny botulinowej typu A w zarejestrowanych wskazaniach w neurologii. Neurologia i Neurochirurgia Polska 44:1, pages 43-64.
Crossref
Crossref
Elena Moro & Marie Vidailhet. 2010. MOVEMENT DISORDERS 4. MOVEMENT DISORDERS 4
474
488
.
Katalin Hahn, Erzsébet Niklai, Ferenc Garzuly & Zoltán Szupera. (2009) Botulinum toxin therapy for focal dystonia. Orvosi Hetilap 150:29, pages 1381-1384.
Crossref
Crossref
C. Beylot. (2009) Les différentes toxines botuliques et leurs spécificités. Annales de Dermatologie et de Vénéréologie 136, pages S77-S85.
Crossref
Crossref
A. R. Bentivoglio, A. Fasano, T. Ialongo, F. Soleti, S. Lo Fermo & A. Albanese. (2009) Fifteen-Year Experience in Treating Blepharospasm with Botox or Dysport: Same Toxin, Two Drugs. Neurotoxicity Research 15:3, pages 224-231.
Crossref
Crossref
Gottfried Kranz, Dietrich Haubenberger, Bernhard Voller, Martin Posch, Peter Schnider, Eduard Auff & Thomas Sycha. (2008) Respective potencies of Botox® and Dysport® in a human skin model: A randomized, double‐blind study. Movement Disorders 24:2, pages 231-236.
Crossref
Crossref
SYRUS KARSAI & CHRISTIAN RAULIN. (2009) Current Evidence on the Unit Equivalence of Different Botulinum Neurotoxin A Formulations and Recommendations for Clinical Practice in Dermatology. Dermatologic Surgery 35:1, pages 1-8.
Crossref
Crossref
Dirk Dressler & Cynthia Comella. 2009. Botulinum Toxin. Botulinum Toxin
398
405
.
K. Wohlfarth, I. Schwandt, F. Wegner, T. Jürgens, G. Gelbrich, A. Wagner, U. Bogdahn & W. Schulte-Mattler. (2008) Biological activity of two botulinum toxin type A complexes (Dysport® and Botox®) in volunteers. Journal of Neurology 255:12, pages 1932-1939.
Crossref
Crossref
Nicolas Roche, Alexis Schnitzler, François Genêt F, Marie-Christine Durand & Djamel Bensmail. (2008) Undesirable Distant Effects Following Botulinum Toxin Type A Injection. Clinical Neuropharmacology 31:5, pages 272-280.
Crossref
Crossref
Allison Brashear. (2008) Clinical Comparisons of Botulinum Neurotoxin Formulations. The Neurologist 14:5, pages 289-298.
Crossref
Crossref
Arnold W. Klein, Alastair Carruthers, Steven Fagien & Nicholas J. Lowe. (2008) Comparisons among Botulinum Toxins: An Evidence-Based Review. Plastic & Reconstructive Surgery 121:6, pages 413e-422e.
Crossref
Crossref
Jean D. A. Carruthers, Richard G. Glogau & Andrew Blitzer. (2008) Advances in Facial Rejuvenation: Botulinum Toxin Type A, Hyaluronic Acid Dermal Fillers, and Combination Therapies???-Consensus Recommendations. Plastic and Reconstructive Surgery 121:SUPPLEMENT, pages 5S-30S.
Crossref
Crossref
Eric Molho, Joseph Jankovic & Mark Lew. (2008) Role of botulinum toxin in the treatment of cervical dystonia. Neurologic Clinics 26, pages 43-53.
Crossref
Crossref
Jan-Willem G. Meijer, Annet A. van Kuijk, Alexander C. H. Geurts, H Jurgen Schelhaas & Machiel J. Zwarts. (2008) Acute Deterioration of Bulbar Function After Botulinum Toxin Treatment for Sialorrhoea in Amyotrophic Lateral Sclerosis. American Journal of Physical Medicine & Rehabilitation 87:4, pages 321-324.
Crossref
Crossref
K. R. Aoki. (2007) Future aspects of botulinum neurotoxins. Journal of Neural Transmission 115:4, pages 567-573.
Crossref
Crossref
Khashayar DashtipourMandana Barahimi & Samia Karkar. (2016) Cervical Dystonia. Journal of Pharmacy Practice 20:6, pages 449-457.
Crossref
Crossref
R. Wenzel, D. Jones & J. A. Borrego. (2007) Comparing two botulinum toxin type A formulations using manufacturers? product summaries. Journal of Clinical Pharmacy and Therapeutics 32:4, pages 387-402.
Crossref
Crossref
Mary Ann Chapman, Rich Barron, David C. Tanis, Chandler E. Gill & P. David Charles. (2007) Comparison of Botulinum Neurotoxin Preparations for the Treatment of Cervical Dystonia. Clinical Therapeutics 29:7, pages 1325-1337.
Crossref
Crossref
Roger Dmochowski & Peter K. Sand. (2007) Botulinum toxin A in the overactive bladder: current status and future directions. BJU International 99:2, pages 247-262.
Crossref
Crossref
Doo-Sik KongKwan Park. (2007) Hemifacial Spasm: A Neurosurgical Perspective. Journal of Korean Neurosurgical Society 42:5, pages 355.
Crossref
Crossref
K. R. Aoki, D. Ranoux & J. Wissel. (2006) Using translational medicine to understand clinical differences between botulinum toxin formulations. European Journal of Neurology 13:s4, pages 10-19.
Crossref
Crossref
Khashayar Dashtipour & Mark Lew. 2006. Handbook of Dystonia. Handbook of Dystonia
137
153
.
Keith A. Foster, Hans Bigalke & K. Roger Aoki. (2009) Botulinum neurotoxin — from laboratory to bedside. Neurotoxicity Research 9:2-3, pages 133-140.
Crossref
Crossref
. (2005) Current awareness: Pharmacoepidemiology and drug safety. Pharmacoepidemiology and Drug Safety 14:10, pages i-xii.
Crossref
Crossref